Immunic Inc. (NASDAQ:IMUX) on Tuesday announced it appointed Michael Panzara as its Chief Medical Officer, effective April 24, 2026, as the company looks to advance its clinical and regulatory strategy.

The late-stage biotechnology company is focused on the development of oral therapies for neurologic diseases.

Panzara will oversee clinical development, medical affairs, and regulatory functions while working closely with leadership.

The appointment marks a leadership transition, with Panzara succeeding Andreas Muehler in the role.

"Notably, during his tenure at Sanofi Genzyme, Mike oversaw the global regulatory approvals of the multiple sclerosis (MS) drugs LEMTRADA and AUBAGIO. During his time at Biogen, he served as global clinical lead for the development of TYSABRI and managed their late-stage portfolio of MS products," stated Daniel Vitt, CEO of Immunic.

Equity Incentive Package Details

As part of his appointment, Immunic's Compensation Committee granted Panzara an inducement equity award.

The package includes an option to purchase 300,000 shares of common stock under the company's 2026 Inducement Equity Compensation Plan.

The grant complies with Nasdaq Listing Rule 5635(c)(4), which allows equity awards as a material inducement for new hires.

Immunic Vesting Structure And Timeline

The stock options are structured with a time-based vesting schedule. Half of the award will vest on the one-year anniversary of April 24, 2026. The remaining portion will vest in equal monthly installments over the following 24 months.

"This is a critically important time in Immunic's evolution and I am excited to be joining the company at such a pivotal inflection point," said Dr. Panzara. "Vidofludimus calcium's potential to treat MS by targeting both immunological and neuroprotective pathways holds promise to redefine the treatment landscape and meaningfully impact the lives of so many people who continue to struggle with their MS. I look forward to building upon the team's successes to further advance Immunic's clinical programs, including the phase 3 ENSURE trials and the planned phase 3 trial of vidofludimus calcium in primary progressive MS."

IMUX Stock Price Activity: Immunic shares were down 3.21% at $9.66 during premarket trading on Tuesday, according to Benzinga Pro data.

Photo Courtesy: Peshkova on Shutterstock